

Adult CIRB - Early Phase Emphasis Meeting Agenda

March 16, 2021

I Continuing Review

10218, A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (Protocol Version Date 09/04/20)

II Continuing Review

10222, A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors (Protocol Version Date 11/10/20)

III Continuing Review

10240, Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy (Protocol Version Date 08/13/20)

IV Continuing Review

10330, A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (Protocol Version Date 08/13/20)

V Memos

10020, A Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer (Protocol Version Date)
